OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility

Introduction: BRAF/MEK inhibitors (dabrafenib/trametinib) are FDA approved for BRAFV600E mutated ATC; however, resistance to kinase inhibitors is universal in solid tumors, thus newer approaches are warranted. Methods: ATC patients with PS </=2 were enrolled on a prospective clinical at a single...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Endocr Soc
Hlavní autoři: Cabanillas, Maria, Busaidy, Naifa, Dadu, Ramona, Ferrarotto, Renata, Gross, Neil, Gule-Monroe, Maria, Lu, Charles, Grosu, Horiana, Williams, Michelle, Zafereo, Mark
Médium: Artigo
Jazyk:Inglês
Vydáno: Endocrine Society 2019
Témata:
Thyroid
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555044/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-OR27-6
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky